Global technology company HCL Technologies and Oracle Health Sciences have partnered to scale up mHealth in clinical trials.

The collaboration will seek to help life sciences companies execute the next-generation of digital clinical trials to save time and lower drug development cost.

The partnership will include the availability of HCL’s Faster Intelligent Trials (FIT) solution using Oracle Health Sciences Mobile Health (mHealth) Connector Cloud Service (Oracle mHealth Cloud).

HCL’s FIT solution can be used to improve patient engagement, collect patient-reported outcomes, monitor patient safety and conduct e-visits during clinical trials.

Also, the FIT solution can be used for remote patient monitoring and as an accompanying application for digital therapies.

HCL North America executive vice-president and business head for life sciences and healthcare Shrikanth Shetty said: “Although many of our customers have already established a strong case for leveraging mHealth technologies in clinical trials or digital therapies through proof of concept, we still see a chasm between the potential and actual adoption at scale.

“As a strategic partner to a large number of life sciences companies, HCL offers a comprehensive portfolio of services to navigate the journey from concept to adoption and continues to support them through the operational support services during or beyond clinical trials.”

The mHealth services portfolio offered by the two companies will help clients across several phases of their journey for easy adoption of mHealth technologies.

Furthermore, Clients planning to adopt Oracle mHealth Cloud as an enterprise platform across all mHealth initiatives will benefit from implementation services provided by HCL.

Oracle Health Sciences global vice-president for product strategy Jim Streeter said: “The life sciences industry has a great opportunity to radically change the way we understand and interact with patients during clinical trials.

“The collaboration between Oracle Health Sciences and HCL enables clinical teams to establish digitally-enabled clinical trial processes and new digital trial methods such as remote patient monitoring.”